27364610|t|Doxifluridine - conjugated 2-5A analog shows strong RNase L activation ability and tumor suppressive effect
27364610|a|RNase L is activated by 2',5'-oligoadenylates (2-5A) at subnanomolar levels to cleave single-stranded RNA. We previously reported the hypothesis that the introduction of an 8-methyladenosine residue at the 2'- terminus of the 2-5A tetramer shifts the 2-5A binding site of RNase L. In this study, we synthesized various 5'- modified 2-5A analog s with 8-methyladenosine at the 2'- terminus. The doxifluridine - conjugated 8-methyladenosine - substituted 2-5A analog was significantly more effective as an activator of RNase L than the parent 5'- monophophorylated 2-5A tetramer and showed a tumor suppressive effect against human cervical cancer cells.
27364610	0	13	Doxifluridine	T114,T121	C0048808
27364610	16	26	conjugated	T082	C0522529
27364610	27	31	2-5A	T114,T121	C0045143
27364610	32	38	analog	T104	C0243071
27364610	45	51	strong	T080	C0442821
27364610	52	59	RNase L	T116,T126	C0071795
27364610	60	70	activation	T045	C0599177
27364610	71	78	ability	T080	C2698977
27364610	83	100	tumor suppressive	T044	C1519692
27364610	101	107	effect	T080	C1280500
27364610	108	115	RNase L	T116,T126	C0071795
27364610	119	128	activated	T045	C0599177
27364610	132	153	2',5'-oligoadenylates	T114,T121	C0045143
27364610	155	159	2-5A	T114,T121	C0045143
27364610	164	176	subnanomolar	T081	C0392762
27364610	177	183	levels	T080	C0441889
27364610	187	193	cleave	T082	C0205242
27364610	194	213	single-stranded RNA	T114	C3272452
27364610	229	237	reported	T170	C0684224
27364610	242	252	hypothesis	T078	C1512571
27364610	262	274	introduction	T169	C0579004
27364610	281	298	8-methyladenosine	T114	C0100309
27364610	318	326	terminus	T082	C1705315
27364610	334	347	2-5A tetramer	T114,T121	C0092311
27364610	348	354	shifts	T169	C0333051
27364610	359	363	2-5A	T114,T121	C0045143
27364610	364	376	binding site	T192	C0005456
27364610	380	387	RNase L	T116,T126	C0071795
27364610	397	402	study	T062	C2603343
27364610	407	418	synthesized	T052	C1883254
27364610	431	439	modified	T169	C0392747
27364610	440	444	2-5A	T114,T121	C0045143
27364610	445	451	analog	T104	C0243071
27364610	459	476	8-methyladenosine	T114	C0100309
27364610	488	496	terminus	T082	C1705315
27364610	502	515	doxifluridine	T114,T121	C0048808
27364610	518	528	conjugated	T082	C0522529
27364610	529	546	8-methyladenosine	T114	C0100309
27364610	549	560	substituted	T052	C1706204
27364610	561	565	2-5A	T114,T121	C0045143
27364610	566	572	analog	T104	C0243071
27364610	577	595	significantly more	T081	C4055637
27364610	596	605	effective	T080	C1704419
27364610	612	621	activator	T052	C1879547
27364610	625	632	RNase L	T116,T126	C0071795
27364610	642	648	parent	T077	C2699423
27364610	653	670	monophophorylated	T044	C1327237
27364610	671	684	2-5A tetramer	T114,T121	C0092311
27364610	698	715	tumor suppressive	T044	C1519692
27364610	716	722	effect	T080	C1280500
27364610	723	730	against	T080	C0521124
27364610	731	736	human	T016	C0086418
27364610	737	752	cervical cancer	T191	C4048328
27364610	753	758	cells	T025	C0007634